for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aptinyx Inc

APTX.OQ

Latest Trade

3.85USD

Change

0.09(+2.39%)

Volume

133,281

Today's Range

3.74

 - 

4.05

52 Week Range

2.88

 - 

29.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.76
Open
3.74
Volume
133,281
3M AVG Volume
3.92
Today's High
4.05
Today's Low
3.74
52 Week High
29.41
52 Week Low
2.88
Shares Out (MIL)
33.66
Market Cap (MIL)
126.58
Forward P/E
-2.01
Dividend (Yield %)
--

Next Event

Aptinyx Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Aptinyx Inc - QTRLY Loss Per Share $0.36

Aptinyx Says Entered Into Sales Agreement With Cowen And Co

Aptinyx Reports Positive Top-Line Data From Mid-Stage Study In Patients With Fibromyalgia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aptinyx Inc

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Industry

Biotechnology & Drugs

Contact Info

1801 Maple Ave Ste 4300

+1.847.8710377

https://www.aptinyx.com/

Executive Leadership

Wilbur H. Gantz

Independent Chairman of the Board

Norbert G. Riedel

President, Chief Executive Officer, Director

Ashish Khanna

Chief Financial Officer, Chief Business Officer

Andrew Kidd

Chief Operating Officer

Joseph R. Moskal

Chief Scientific Officer

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-2.640

2019(E)

-1.868
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.34
Price To Book (MRQ)
1.01
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.93
Return on Equity (TTM)
-36.44

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up